Analysis of the expression of the Serpina1 gene in SARS-CoV-2 infection : study of a new biomarker
Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved..
INTRODUCTION: The SERPINA1 gene encodes the protein Alpha-1 Antitrypsin (AAT1). Possible imbalances between the concentrations of proteases and antiproteases (AAT1) can lead to the development of serious pulmonary and extrapulmonary pathologies. In this work we study the importance of this possible imbalance in patients with COVID-19.
OBJECTIVES: To correlate the severity of the symptoms of SARS-COV-2 infection with the AAT1 concentrations at diagnosis of the disease.
METHODS: An observational, prospective, cross-sectional, non-interventional, analytical study was carried out where 181 cases with COVID-19 admitted to the "Lozano Blesa" University Clinical Hospital of Zaragoza were selected. The concentration of AAT1 was studied in all of them and this was correlated with the clinical aspects and biochemical parameters at hospital admission.
RESULTS: 141 cases corresponded to patients with severe COVID and 40 patients with mild COVID. AAT1 levels were positively correlated with the days of hospitalization, severity, C-Reactive Protein, ferritin, admission to Intensive Care, and death, and presented a negative correlation with the number of lymphocytes/mm3. AAT1 concentrations higher than 237.5 mg/dL allowed the patient to be classified as "severe" (S72%; E78%) and 311.5 mg/dL were associated with the risk of admission to Intensive Care or Exitus (S67%; E79%).
CONCLUSIONS: Levels of the SERPINA1 gene expression product, AAT1, correlate with the severity of COVID-19 patients at diagnosis of the disease, being useful as a prognostic biomarker.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Revista clinica espanola - (2024) vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pintanel-Raymundo, M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alfa-1 antitripsina |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.rceng.2024.04.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370980425 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370980425 | ||
| 003 | DE-627 | ||
| 005 | 20240426234255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240413s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rceng.2024.04.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM370980425 | ||
| 035 | |a (NLM)38608729 | ||
| 035 | |a (PII)S2254-8874(24)00053-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pintanel-Raymundo, M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of the expression of the Serpina1 gene in SARS-CoV-2 infection |b study of a new biomarker |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved. | ||
| 520 | |a INTRODUCTION: The SERPINA1 gene encodes the protein Alpha-1 Antitrypsin (AAT1). Possible imbalances between the concentrations of proteases and antiproteases (AAT1) can lead to the development of serious pulmonary and extrapulmonary pathologies. In this work we study the importance of this possible imbalance in patients with COVID-19 | ||
| 520 | |a OBJECTIVES: To correlate the severity of the symptoms of SARS-COV-2 infection with the AAT1 concentrations at diagnosis of the disease | ||
| 520 | |a METHODS: An observational, prospective, cross-sectional, non-interventional, analytical study was carried out where 181 cases with COVID-19 admitted to the "Lozano Blesa" University Clinical Hospital of Zaragoza were selected. The concentration of AAT1 was studied in all of them and this was correlated with the clinical aspects and biochemical parameters at hospital admission | ||
| 520 | |a RESULTS: 141 cases corresponded to patients with severe COVID and 40 patients with mild COVID. AAT1 levels were positively correlated with the days of hospitalization, severity, C-Reactive Protein, ferritin, admission to Intensive Care, and death, and presented a negative correlation with the number of lymphocytes/mm3. AAT1 concentrations higher than 237.5 mg/dL allowed the patient to be classified as "severe" (S72%; E78%) and 311.5 mg/dL were associated with the risk of admission to Intensive Care or Exitus (S67%; E79%) | ||
| 520 | |a CONCLUSIONS: Levels of the SERPINA1 gene expression product, AAT1, correlate with the severity of COVID-19 patients at diagnosis of the disease, being useful as a prognostic biomarker | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alfa-1 antitripsina | |
| 650 | 4 | |a Alpha-1 antitrypsin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a SERPINA1 | |
| 700 | 1 | |a Menao-Guillén, S |e verfasserin |4 aut | |
| 700 | 1 | |a Perales-Afán, J J |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gutiérrez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno-Gázquez, I |e verfasserin |4 aut | |
| 700 | 1 | |a Julián-Ansón, M |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Álvarez, M |e verfasserin |4 aut | |
| 700 | 1 | |a Olivera-González, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Cía, I |e verfasserin |4 aut | |
| 700 | 1 | |a Torralba-Cabeza, M A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista clinica espanola |d 2013 |g (2024) vom: 10. Apr. |w (DE-627)NLM21591063X |x 2254-8874 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rceng.2024.04.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 04 | ||